Table 1 Patient demographic and clinical characteristics

From: Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

N (%)

VTD4 (n = 129)

VTD6 (n = 61)

P value

Age, median (range) years

55.6 (30–63)

55.4 (40–64)

0.866

Gender

  

0.27

 Male

73 (56.6)

40 (65.6)

 

 Female

56 (43.4)

21 (34.4)

 

ECOG PS

 0

35 (27.1)

13 (21.3)

0.334

 1

68 (52.7)

30 (49.2)

 

 2

26 (20.2)

18 (28.5)

 

R-ISS

  

0.421

 I

37 (28.7)

15 (24.6)

 

 II

61 (47.3)

35 (57.4)

 

 III

31 (24.0)

11 (18.0)

 

Albumin, g/L, median (range)

3.75 (2.0–6.0)

3.63 (2.0–5.5)

0.379

β2-Microglobulin ≥ 5.5 mg/L

41 (31.8)

18 (29.5)

0.752

LDH > normal

25 (19.4)

7 (11.5)

0.215

Creatinine level, mmol/L, median (range)

1.14 (0.53–8.26)

1.27 (0.68–11.96)

0.127

Hemoglobin level, g/dL, median (range)

10.1 (6.0–16.2)

10.0 (4.0–15.0)

0.192

Calcium level, mmol/L, median (range)

9.32 (7.0–13.2)

9.22 (6.2–15.3)

0.771

Plasma cells in bone marrow ≥ 60%

52 (40.6)

23 (37.7)

0.752

FISH*

 t(4;14)

20 (18.5)

12 (26.7)

0.564

 t(14;16)

5 (4.6)

6 (13.3)

0.179

 t(14;20)

2 (1.6)

2 (4.1)

0.225

 17p13 deletion

12 (11.1)

9 (20.0)

0.322

Amplification of 1q21

41 (40.0)

11 (24.4)

0.056

  1. Data are presented as number (%) unless otherwise indicated. VTD4 indicates four cycles of bortezomib, thalidomide, and dexamethasone; and VTD6 indicates six cycles of bortezomib, thalidomide, and dexamethasone. ECOG PS Eastern Cooperative Oncology Group performance status, R-ISS revised international staging system, LDH lactate dehydrogenase, FISH fluorescent in situ hybridization
Back to article page